Retham Technologies

Retham Technologies

Biotechnology, 1225 Discovery Pkwy, Milwaukee, Wisconsin, 53226, United States, 1-10 Employees

rethamtechnologies.com

  • LinkedIn

phone no Phone Number: +14*********

Who is RETHAM TECHNOLOGIES

Retham TechnologiesTM LLC was established in 2017 to translate recent discoveries into a life-saving in vitro diagnostic (IVD) assay that provides earlier and more accurate in-hospital di...

Read More

map
  • 1225 Discovery Pkwy, Milwaukee, Wisconsin, 53226, United States Headquarters: 1225 Discovery Pkwy, Milwaukee, Wisconsin, 53226, United States
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from RETHAM TECHNOLOGIES

Retham Technologies Org Chart and Mapping

Employees

Curtis Jones

Vice President, Research & Innovation

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Retham Technologies

Answer: Retham Technologies's headquarters are located at 1225 Discovery Pkwy, Milwaukee, Wisconsin, 53226, United States

Answer: Retham Technologies's phone number is +14*********

Answer: Retham Technologies's official website is https://rethamtechnologies.com

Answer: Retham Technologies's revenue is Under $1 Million

Answer: Retham Technologies's SIC: 2836

Answer: Retham Technologies's NAICS: 541714

Answer: Retham Technologies has 1-10 employees

Answer: Retham Technologies is in Biotechnology

Answer: Retham Technologies contact info: Phone number: +14********* Website: https://rethamtechnologies.com

Answer: Retham TechnologiesTM LLC was established in 2017 to translate recent discoveries into a life-saving in vitro diagnostic (IVD) assay that provides earlier and more accurate in-hospital diagnosis of Heparin-induced Thrombocytopenia (HIT). HIT is a serious adverse reaction to the blood thinner heparin. It is characterized by a drop in platelet count (thrombocytopenia) and in ~1/3rd of cases, causes blood clotting (thrombosis) that can result in life-and-limb threatening consequences such as amputation, stroke and death. The diagnosis of HIT is challenging. A family of easy-to-run tests called PF4 ELISAs is performed in the hospital laboratory but have high false positive rates, i.e. many patients positive for antibodies to PF4:polyanion complexes do not have clinical HIT. A second test, the Serotonin release assay (SRA), is considered the gold-standard test for HIT; but, it is performed only at a handful of laboratories nationally on a small fraction of suspected cases due to technical complexity, cost and turnaround time concerns. Thus, >90% of HIT suspected patients are currently managed using PF4 ELISAs, and thousands of patients receive costly non-heparin anticoagulant therapy due to false positive diagnoses. These alternative anticoagulants have a worse bleeding risk profile relative to heparin often resulting in severe or fatal hemorrhage. Retham TechnologiesTM is developing HITDxTM, an IVD assay for early and accurate near-patient HIT diagnosis that is expected to facilitate timely and appropriate therapy thereby leading to better outcomes.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access